OMT Therapeutics is developing a portfolio of heavy-chain antibodies (UniAbs) for the treatment of cancer and infectious diseases.
Potential partnerships include development rights for: monospecific, bispecific, or polyspecific proteins.
Polyspecific proteins, made by fusing the binding sites (VDJ fragments or UniDabs) of UniAbs into a single protein, have broad reactivities. The binding of UniDabs to human serum albumin or immunoglobulin guarantee long half-lives.
Licenses for OMT Therapeutics technology provide patent-based exclusivity and freedom to operate. For more information, please use this email link: email@example.com